HER2 Amplification Ratios by Fluorescence In Situ Hybridization and Correlation with Immunohistochemistry in a Cohort of 6556 Breast Cancer Tissues
Top Cited Papers
- 1 April 2004
- journal article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 5 (1), 63-69
- https://doi.org/10.3816/cbc.2004.n.011
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Prognostic and predictive value of HER2/neu oncogene in breast cancerMicroscopy Research and Technique, 2002
- Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast CarcinomaLaboratory Investigation, 2000
- HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization ApproachLaboratory Investigation, 2000
- HER-2/neu Gene Amplification Compared With HER-2/neu Protein Overexpression and Interobserver Reproducibility in Invasive Breast CarcinomaAmerican Journal of Clinical Pathology, 2000
- Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assaysJournal of Clinical Pathology, 2000
- Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ HybridizationLaboratory Investigation, 2000
- HER-2/neu Assessment in Breast Cancer by Immunohistochemistry and Fluorescence In Situ Hybridization: Comparison of Results and Correlation With SurvivalMolecular Diagnosis, 2000
- Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocolCancer, 1994
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987